作者: Collet Dandara , Collen Masimirembwa , Yosr Z. Haffani , Bernhards Ogutu , Jenniffer Mabuka
DOI: 10.12688/AASOPENRES.12965.1
关键词:
摘要: The African Pharmacogenomics Consortium (APC) was formally launched on the 6th September 2018. This white paper outlines its vision, and objectives towards addressing challenges of conducting applying pharmacogenomics in Africa identifies opportunities for advancement individualized drugs use continent. Africa, especially south Sahara, is beset with a huge burden infectious diseases much co-morbidity whose multiplicity intersection are major achieving sustainable development goals (SDG), SDG3, health wellness. profile commonly used populations lead to different spectrum adverse drug reactions (ADRs) when compared other parts world. Coupled genetic diversity among Africans, APC established promote research clinical implementation safe effective medicine continent. Variation way patients respond treatment mainly due differences activity enzymes transporters involved pathways associated each drug’s disposition. Knowledge pharmacogenomics, therefore, helps identifying variants these proteins their functional effects. needs consolidate expertise technological platforms bring use.